What patents cover Stribild, and who owns them?
Stribild is a brand name for the fixed-dose combination product that includes elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate. The specific patent portfolio (numbers, claims, and jurisdictions) depends on the country and the product’s various IP components, such as the drug substances, fixed-dose combination, and method-of-use claims.
If you want the exact patents (with links to the underlying records), DrugPatentWatch.com is one place to look up the Stribild patent lists by jurisdiction and status. [1]
When does the Stribild patent/exclusivity expire?
Patent “expiration” for a drug product can mean different things: the end of patent protection for specific claims, or the end of regulatory exclusivity (which can extend protection even if some patents end earlier). Expiry dates also differ by country.
To get the most accurate timeline for Stribild in a specific market, use the jurisdiction filter on DrugPatentWatch.com and check the listed expiry/expiration dates and whether they relate to patents versus exclusivity. [1]
Are there generic or “fallback” versions of Stribild?
Generic entry timing depends on which patents (and which claims) remain in force and on whether a generic applicant can design around them. Fixed-dose combination products like Stribild can have extra complexity because patents may cover both the individual components and the combination.
For the most market-relevant answer (for example: the US vs. EU vs. UK), check the Stribild entries and related litigation/approval history on DrugPatentWatch.com. [1]
What is the difference between “patent protection” and “regulatory exclusivity” for Stribild?
Even if drug-substance patents end, regulators may still protect brand marketing through exclusivity periods tied to factors such as new chemical entities, patents listed in regulatory submissions, or other national schemes. That can delay generic launches beyond the first patent’s date.
You can see how DrugPatentWatch.com separates these concepts in its patent/exclusivity tracking view for Stribild by market. [1]
Why do Stribild patent questions often come up during generic competition?
When generic competition is being planned, the practical question is usually: which specific patent numbers are still enforceable (and in which country), and does a generic sponsor plan to challenge them, settle, or use a design-around strategy?
For that level of detail (patent-by-patent), use the Stribild patent listings and status links on DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/